Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis
2017; Springer Nature; Volume: 32; Issue: 4 Linguagem: Inglês
10.1038/leu.2017.330
ISSN1476-5551
AutoresAnimesh Pardanani, Jason Gotlib, Andrew W. Roberts, Martha Wadleigh, Shireen Sirhan, Jun Kawashima, Julie Maltzman, Lixin Shao, Vikas Gupta, Ayalew Tefferi,
Tópico(s)Kruppel-like factors research
Referência(s)